Ignite Creation Date:
2024-05-19 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06413043
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-04-29
Brief Title:
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy
Sponsor:
All India Institute of Medical Sciences Bhubaneswar
Organization:
All India Institute of Medical Sciences Bhubaneswar
Study Overview
Official Title:
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy A Randomized Control Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Study on efficacy of add on selenium in mild-to-moderate Graves ophthalmopathy A Randomized Control Trial The study aims to evaluate the response of adding selenium in patients with Graves ophthalmopathy focusing on improving quality of life CAS scoring and thyroid status The methodology involves a Randomized Control Trial with a sample size of 78 patients Patients meeting specific criteria will receive either standard treatment with Anti Thyroid Drugs and Vitamin B complex or add on selenium with Vitamin B complex for 6 months Outcome measures include CAS score reduction thyroid function improvement and quality of life enhancement The study will last 18 months with various investigations and ethical considerations outlined The document emphasizes the importance of early diagnosis of Graves Ophthalmopathy to prevent vision loss and deformity highlighting the significance of informed patients and healthcare professionals regarding TED symptoms and risk factors
Detailed Description:
The Study on efficacy of add on selenium in mild-to-moderate Graves ophthalmopathy A Randomized Control Trial The study aims to evaluate the response of adding selenium in patients with Graves ophthalmopathy focusing on improving quality of life CAS scoring and thyroid status The methodology involves a Randomized Control Trial with a sample size of 78 patients Patients meeting specific criteria will receive either standard treatment with Anti Thyroid Drugs and Vitamin B complex or add on selenium with Vitamin B complex for 6 months Outcome measures include CAS score reduction thyroid function improvement and quality of life enhancement The study will last 18 months with various investigations and ethical considerations outlined The document emphasizes the importance of early diagnosis of Graves Ophthalmopathy to prevent vision loss and deformity highlighting the significance of informed patients and healthcare professionals regarding TED symptoms and risk factors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None